-
Min Investment
-
$250
-
Offering Date
-
July 05, 2021
-
Target Raise
-
$200.00K
Company Description
Naturally grown high-value compounds for a healthy life. Our patented biosynthetic methods, using yeast fermentation, ensure the efficient production of high-quality compounds.
Key Deal Facts
4 patents pending producing the best results in the space.
Producing 99% pharmaceutical grade compounds, Bioorganic, Non GMO, at 70-90% less than large volume wholesale prices.
Successfully biosynthesized CBG/CNGA, THCV/THCVA and CBN/CBNA.
Benefits of CBG Reduces pain, inflammation helps treat Inflammatory Bowel Disease IDB, Glaucoma, Huntington's disease.
THCV Appetite suppressant, Helps Diabetes, reduces inflammation, Neuroprotectant, bone growth.
Over 70 articles published on company Forbes, Bloomberg, Nasdaq, Reuters, Maxim, Rolling Stones.
Research partnerships Institute of Genetics Moscow, Demark Technical university, Imperial College UK.
Sustainable production using 90% less energy and natural resources than cultivators.
Management Team / Advisory Board Bios
Maxim Mikheev, CEO / Chief Scientist
Max is a medical, life sciences, computer sciences expert who received numerous patents, grants, and professional honors. He co-invented many patented genetic modifications and co-founded several biotech startups.
Dennis O'Neill, President
Dennis O'Neill has over 25 years of experience as an Investment Banker. He raised over 2 billion dollars in capital for early-stage companies.
Difeng Gao, Ph.D., Lead Scientist
Difeng is an accomplished scientist with 10+ years of molecular biology experience, including 6 years of experience with Yarrowia Lipolytica, CRISPR, and simultaneous integration of multiple genes.
